What the 2025 USP <467> revision means for residual solvents testing in MENA

The 2025 revision of USP <467> tightens Class 2 solvent limits and reshapes the validation work pharma QC labs in Egypt and the GCC need to plan for in 2026. The short version: most labs need a method requalification, not a method rewrite.
What actually changed
Three of the Class 2 solvents got tighter PDE limits, and the headspace method's system-suitability criteria were rewritten to be performance-based rather than peak-shape-based. The change isn't huge in absolute terms but it is enough to push borderline methods over the line.
Who is most affected in the region
QC labs running multi-product GC-headspace methods on shared instrumentation. If your method was validated to the older limits with a comfortable margin, you're probably fine. If your validation report shows you were running with single-digit-percent margin against the spec, you need a requalification.
The validation work, in order
Run a five-replicate accuracy check at the new limit. Confirm linearity from LOQ to 120% of the new limit. Re-establish the limit of quantitation if your method documentation cites a value above the new spec. Update SOPs and operator training records.
Why we're flagging it now
The transition window in most regulatory regimes is 12 months from publication. For Egyptian and Gulf labs registering products in markets that adopt USP by reference, that clock has been running since late 2025. Plan the requalification work into your Q1 2026 schedule.
Have a question about your application?
Our applications team can walk through method development, instrument selection, or compliance scoping for your lab. Tell us what you're working on.
Talk to an applications specialist
Send a short note and we'll match you with the right engineer on our team.
